BTIG analyst Ryan Zimmerman maintained a Buy rating on Globus Medical (NYSE:GMED) on Wednesday, setting a price target of $63, which is approximately 26.91% above the present share price of $49.64.
Zimmerman expects Globus Medical to post earnings per share (EPS) of $0.26 for the third quarter of 2020.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Globus Medical, with an average price target of $55.09.
The analysts price targets range from a high of $61 to a low of $50.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $190.58 million and a net profit of $29 million. The company's market cap is $4.75 billion.
According to TipRanks.com, BTIG analyst Ryan Zimmerman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 11.9% and a 53.27% success rate.
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.